These 3 biotech stocks are about to break out - one could double your money

30%, 44%, and 103% gains are on the way... You are receiving this as part of your free subscription to Money Morning Stock VQScore™. To remove your email from this list, unsubscribe here.

Click here to access your top-25 ranked stocks! Starting Monday, This 40x Phenomenon Can Hand You $30,000 a MONTH It's already made history. The profit opportunities are already rolling in one after the other. And when YOU take advantage of this market phenomenon, you can pocket massive, life-changing windfalls. The next V3 recommendation is going live first thing Monday morning - and the profits at stake here could be earth-shattering. You only have a matter of hours before this kicks into full force. While you still have time to prepare, take a look at the V3 Effect in action... August 29, 2019 These 3 Biotech Stocks Are Recession-Proof Dear VQScore Member, Top-Ranked Stocks on the Move Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX), Ranked No. 7 MDRX earned the No. 7 overall position in our Money Morning Stock VQScore™ Top 25 for the second time this week. We're excited to share this turnaround company because profits went from a loss of $196 million in 2017 to a positive $363 million in 2018. We expect that trend to continue through 2020. You can find our full rankings, including our No. 1 stock, here. 72% and Climbing... Since VQScore™ identified Kinross Gold Corp. (NYSE: KGC) as a "Strong Buy" exactly one year ago today, the stock has rocketed 72% higher. That's compared to a -0.7% return you would have yielded owning the S&P 500. With the price of physical gold on the rise as recession fears sink into the market, gold miners like Kinross generally outperform. Look for KGC stock to continue rising if these conditions persist. With recession indicators flashing, many are wondering if this is the end of a historic 10-year-plus bull market. Regardless of which way the overall market moves next, our proprietary Money Morning Stock VQScore™ algorithm finds profitable stocks with money-doubling potential. And that's just what we have for you today. Our top three biotech stocks could make you 30%, 44%, and 103%, respectively. No matter what the economy does, medical patients around the world still require pain-relieving and lifesaving medication. We're not talking about companies that make aspirin or joint ointments... The biopharmaceutical companies we found for you today are working to treat HIV, multiple sclerosis, and other inflammatory diseases affecting millions around the globe. All three have patented staple drugs that fuel profits. But almost all investors on Wall Street are overlooking the major pipeline drugs each company has. These drugs could produce exponential revenue that could seriously jolt the bottom line when passed by the FDA. And the probability each passes is quite high... Here they are. Sincerely, Kyle Anderson Head of VQ Research The Brand-New VQScore Forum Is Live The Money Morning VQScore Forum is comprised of like-minded individuals, all dedicated to profitable, independent investing. It's an opportunity for you to interact with the entire community - our VQScore team and other VQScore Members like yourself. You're invited to go here and get started on the Forum. We'd love to hear what you think, so drop us a line if anything comes to mind. Unsubscribe from Money Morning Stock VQScore™ Manage Your Email Preferences You are receiving this e-mail at its028@gmail.com as a part of your free subscription to the Money Morning Stock VQScore™. To read our privacy policy click here. To cancel by mail or for any other subscription issues, write us at: Money Morning Stock VQScore™ | Attn: Member Services | 1125 N. Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://moneymorning.com © 2019 Money Morning Stock VQScore™ All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any recommendations in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning Stock VQScore™. 1125 N. Charles Street, Baltimore MD 21201.